RUA Stock Overview
Engages in the provision of polymers, services, and products to the medical device industry in Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
RUA Life Sciences plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.11 |
| 52 Week High | UK£0.59 |
| 52 Week Low | UK£0.085 |
| Beta | 1.12 |
| 11 Month Change | -21.05% |
| 3 Month Change | 2.27% |
| 1 Year Change | -48.86% |
| 33 Year Change | -92.45% |
| 5 Year Change | -86.02% |
| Change since IPO | -99.19% |
Recent News & Updates
Shareholder Returns
| RUA | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0.9% | 5.6% | -0.3% |
| 1Y | -48.9% | -1.6% | 6.1% |
Return vs Industry: RUA underperformed the UK Medical Equipment industry which returned -2.1% over the past year.
Return vs Market: RUA underperformed the UK Market which returned 5.6% over the past year.
Price Volatility
| RUA volatility | |
|---|---|
| RUA Average Weekly Movement | 9.6% |
| Medical Equipment Industry Average Movement | 6.0% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: RUA's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: RUA's weekly volatility has decreased from 15% to 10% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 40 | Bill Brown | rualifesciences.com |
RUA Life Sciences plc, together with its subsidiaries, engages in the provision of polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates through Biomaterials, Contract Manufacture, Vascular, and Structural Heart segments. The Biomaterials segment operates as depository of the Intellectual Property and licensing rights to a range of biostable and implantable polymers, including Elast-Eon and ECSil.
RUA Life Sciences plc Fundamentals Summary
| RUA fundamental statistics | |
|---|---|
| Market cap | UK£6.98m |
| Earnings (TTM) | -UK£1.44m |
| Revenue (TTM) | UK£2.19m |
3.2x
P/S Ratio-4.8x
P/E RatioIs RUA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RUA income statement (TTM) | |
|---|---|
| Revenue | UK£2.19m |
| Cost of Revenue | UK£475.00k |
| Gross Profit | UK£1.72m |
| Other Expenses | UK£3.16m |
| Earnings | -UK£1.44m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.023 |
| Gross Margin | 78.32% |
| Net Profit Margin | -65.72% |
| Debt/Equity Ratio | 2.3% |
How did RUA perform over the long term?
See historical performance and comparison